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Long-Term Safety and Tolerability of Apremilast Versus 
Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of 
Three Phase III, Randomized, Controlled Trials
Philip J. Mease,1 Dafna D. Gladman,2 Juan J. Gomez-Reino,3 Stephen Hall,4 Arthur Kavanaugh,5 
Eric Lespessailles,6 Georg Schett,7  Maria Paris,8 Nikolay Delev,9 Lichen Teng,8 and Jürgen Wollenhaupt10
Objective. Psoriatic arthritis (PsA) requires long-term treatment, yet safety concerns and monitoring requirements 
make maintenance a challenge. This analysis of pooled Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 
(PALACE) 1, 2, and 3 data describes 3-year apremilast safety and tolerability in PsA.
Methods. Patients with active PsA were randomized (1:1:1) to placebo, apremilast 30 mg twice daily, or apremilast 
20 mg twice daily. Placebo patients were re-randomized to apremilast 30 mg twice daily or 20 mg twice daily at week 
16 (early escape) or 24. Double-blind treatment continued to week 52; patients could continue apremilast during an 
open-label, long-term treatment phase.
Results. In total, 1493 patients received at least one dose of study medication and were included in the safety 
population (placebo: n = 495; apremilast 30 mg: n = 497; apremilast 20 mg: n = 501). Among patients receiving 
apremilast, 53.2% (767/1441) completed 3 years of treatment. Greater rates of adverse events (AEs) were reported 
with apremilast (61.1%; exposure-adjusted incidence rate [EAIR]/100 patient-years, 265.1) versus placebo (47.5%; 
EAIR/100 patient-years, 200.7) in the placebo-controlled period. During weeks 0 to ≤52, the most common AEs 
occurring in apremilast-exposed patients were diarrhea (13.9%; EAIR/100 patient-years, 18.6), nausea (12.3%; 
EAIR/100 patient-years, 16.0), headache (9.4%; EAIR/100 patient-years, 12.1), upper respiratory tract infection 
(9.1%; EAIR/100 patient-years, 11.5), and nasopharyngitis (6.2%; EAIR/100 patient-years, 7.7). Most AEs were 
mild/moderate with apremilast exposure ≤156 weeks. Rates of depression remained low (EAIR/100 patient-years, 
1.8). Major adverse cardiac events (EAIR/100 patient-years, 0.5), malignancies (EAIR/100 patient-years, 0.9), and 
serious opportunistic infections (EAIR/100 patient-years, 0.0) were infrequent over the 3-year exposure period. 
Discontinuation rates due to AEs were low (<7.5%) across all apremilast-exposure periods. Incidences of clinically 
meaningful abnormalities in postbaseline laboratory values was low; most values returned to baseline levels with 
continued treatment and without intervention.
Conclusion. Apremilast demonstrated a favorable safety profile and was well tolerated up to 156 weeks.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic disease requiring long-
term treatment to achieve continuous control of systemic inflam-
mation and to minimize joint damage and physical disability (1–3). 
Rheumatologists and patients report difficulties in choosing and 
adhering to a treatment regimen for active PsA because of safety 
concerns (4,5). Many patients discontinue a prescribed conven-
tional or biologic disease-modifying antirheumatic drug (DMARD) 
within 12 months in part because of adverse events (AEs) (6,7), 
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and treatment is limited by concerns about long-term safety and 
tolerability and ongoing safety monitoring requirements due to 
laboratory abnormalities (4,5) as well as loss of response due to 
immunogenicity with biologics (8,9).
In addition, PsA has been linked to an increased risk of certain 
comorbidities, including cardiovascular events such as myocar-
dial infarction (MI) and stroke (10,11), gastrointestinal (GI) diseases 
such as Crohn disease, ulcerative colitis, peptic ulcer disease, and 
irritable bowel syndrome (12), and depression (13), making cardio-
vascular and GI safety and risk of depression with PsA treatments 
important considerations when choosing treatment. Findings on 
the underlying risk of malignancy in PsA are limited and mixed, 
with comparisons of general population cohorts revealing a similar 
(14) or greater (15) incidence of malignancy in patients with PsA.
Apremilast is an oral phosphodiesterase 4 (PDE4) inhib-
itor that works within immune cells to modulate the production 
of multiple inflammatory mediators implicated in the pathogenesis 
of PsA (16). Apremilast has demonstrated efficacy and safety in 
the Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 
(PALACE) 1, 2, and 3 phase III studies in patients with active PsA 
despite prior conventional DMARDs and/or biologics, including 
biologic failures (limited to ≤10%) (17–19). These studies are con-
tinuing to evaluate the efficacy and safety of apremilast treatment 
for up to 5 years.
The current report describes the long-term safety of apremi-
last treatment for up to 3 years, based on a large pooled database 
of patients from the PALACE 1, 2, and 3 studies.
METHODS
Study design. PALACE 1 (NCT01172938), PALACE 2 
(NCT01212757), and PALACE 3 (NCT01212770) are phase 
III, multicenter, randomized, double-blind, placebo-controlled 
studies with similar designs. Full details of the study designs 
and methods have been previously published (18–20). After the 
placebo-controlled period (weeks 0 to 24), all patients received 
apremilast 30 or 20 mg twice daily and continued double-blind 
treatment through week 52. Upon completion of the 52-week, 
double-blind period, patients were eligible to enter a long-term, 
open-label extension phase, for a total follow-up of up to 5 years.
Institutional review boards at each investigation site approved 
the study protocols in accordance with the Declaration of Helsinki 
and the International Conference on Harmonisation Guideline E6: 
Good Clinical Practice. All patients provided written informed con-
sent before any study-related procedures were done.
Key inclusion/exclusion criteria. Adult patients (≥18 
years of age) with a documented diagnosis of PsA for ≥6 months 
who met the Classification Criteria for Psoriatic Arthritis (CASPAR) 
at study entry were eligible to participate if they had at least three 
swollen and at least three tender joints despite past or current 
DMARDs. Patients with prior use of conventional DMARDs and/
or biologics, including failures, were permitted, and tumor necro-
sis factor blocker efficacy failures were limited to 10% or fewer 
patients. Patients were not allowed to have therapeutic failure 
of more than three agents for PsA (conventional DMARDs or bio-
logics) or more than one tumor necrosis factor blocker. Patients 
in PALACE 3 were required to have at least one plaque psoriasis 
lesion 2 cm or larger. Patients were excluded from the study if 
they had tuberculosis, HIV, hepatitis B or C infection, malignan-
cies (with some exceptions), any other significant comorbidities or 
laboratory abnormalities, or past exposure to certain medications.
Concomitant medications. Patients taking concurrent 
DMARDs at baseline were allowed to continue stable doses 
of methotrexate (≤25 mg/wk), leflunomide (≤20 mg/d), sul-
fasalazine (≤2 g/d), or a combination thereof; other DMARDs or 
immunosuppressive systemic therapies were prohibited. A sin-
gle reduction in DMARD dose was allowed after week 24. Low 
potency topical corticosteroids were allowed within specific 
parameters. Stable doses of nonsteroidal anti-inflammatory drugs 
(NSAIDs), narcotic analgesics, or oral corticosteroids (prednisone 
≤10 mg/d or an equivalent) were permitted. After week 52, if a 
patient had worsening of PsA activity, the investigator could adjust 
or add concomitant treatment with an NSAID (change type and/
or dose), conventional DMARD (add or increase dose or change 
route of administration [methotrexate]), or corticosteroid (intra-
muscular injections or short courses of oral tablets), within specific 
parameters. Topical therapy or phototherapy was permitted for 
patients with worsening skin psoriasis after week 52.
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Safety analysis. Safety outcomes were analyzed among 
the safety population, which included all patients who received 
at least one dose of study medication. Patient disposition relative 
to the start of apremilast treatment was provided by apremi-
last-exposure period, and retention rates were presented by 
Kaplan-Meier plots. Safety outcomes were summarized descrip-
tively. Safety assessments included collection of AEs, clinical 
laboratory testing, physical examination findings, and vital signs 
at each visit and 12-lead electrocardiogram at screening; base-
line; weeks 16, 24, and 52; and at 52-week intervals during the 
long-term, open-label extension phase as well as in the event of 
early withdrawal. Clinically meaningful changes in hematology and 
clinical chemistry postbaseline laboratory values were predefined 
and included alanine aminotransferase more than three times the 
upper limit of normal (ULN), aspartate aminotransferase more than 
three times the ULN, creatinine >1.7 × ULN, leukocytes <1.5 × 
109/l, neutrophils <1 × 109/l, platelets <75 × 109/l, and hemoglobin 
<10.5 g/dl for men and <8.5 g/dl for women.
Safety data were assessed by actual exposure to placebo, 
apremilast 30 mg twice daily, and apremilast 20 mg twice daily. 
Placebo-exposure data included data through 16 weeks of expo-
sure for placebo patients who escaped and data through 24 weeks 
for patients who continued on placebo until 24 weeks. Apremilast 
exposure data included all available apremilast treatment data for 
all patients who received at least one dose of apremilast. These 
data were assessed by length of exposure (0 to ≤52 weeks, >52 
to ≤104 weeks, and >104 to ≤156 weeks). When no long-term 
placebo-exposure data were available for comparison, expo-
sure-adjusted incidence rates (EAIRs) were used to assess rare 
instances, such as major adverse cardiac events (MACEs), malig-
nancies, and serious infections, during 0 to ≤52, 0 to ≤104, and 0 
to ≤156 weeks of exposure. EAIR/100 patient-years is defined as 
100 times the number of patients (n) reporting the event divided by 
patients’ total exposure, up to the first event start date for patients 
reporting the event, in years.
RESULTS
Patients. A total of 1493 patients received at least one dose 
of study medication and were included in the safety population 
(placebo: n = 495; apremilast 30 mg: n = 497; apremilast 20 mg: 
n = 501). Of those who were treated with apremilast, 53.2% 
(767/1441) completed 3 years of apremilast treatment (Figures 1 
and 2). The most commonly reported reasons for discontinuation 
of apremilast treatment during the apremilast-exposure periods 
are shown in Figure 1. The five most common AEs reported as 
leading to discontinuation of apremilast throughout the three expo-
sure periods were nausea (n = 24), diarrhea (n = 22), headache 
(n = 16), upper abdominal pain (n = 7), and vomiting (n = 7). In the 
weeks 0 to ≤52 period, 1441 patients received apremilast twice 
daily (30 mg: n = 721, patient-years = 608.7; 20 mg: n = 720, 
patient-years = 600.6). In the weeks >52 to ≤104 period, 1028 
patients received apremilast twice daily (30 mg: n = 520, patient-
years = 477.9; 20 mg: n = 508, patient-years = 459.9). During 
weeks >104 to ≤156 of the apremilast-exposure period, 865 
patients received apremilast twice daily (30 mg: n = 443, patient-
years = 424.4; 20 mg: n = 422, patient-years = 395.1).
Baseline patient demographics, disease characteristics, 
and prior and concurrent therapy were comparable across 
treatment groups (Table 1). In the overall study population, 
most patients (92.4%) had a history of at least one comorbid 
illness at baseline. The most common comorbid conditions 
were hypertension (40.1%), hypercholesterolemia (15.1%), 
depression (14.5%), gastroesophageal reflux disorder (13.0%), 
and obesity (11.9). In line with this pattern of comorbidities, 
some of the most frequently used concurrent medications 
were for acid-related disorders (29.8%), renin-angiotensin 
system antagonists (28.1%), lipid-modifying agents (20.9%), 
psychoanaleptics (14.7%), beta-blocking agents (13.9%), 
calcium channel blockers (11.1%), and medications for diabetes 
control (10.3%).
AE overview. During the placebo-controlled phase, 47.5% 
(EAIR/100 patient-years, 200.7) of patients receiving placebo, 
60.8% (EAIR/100 patient-years, 272.0) of patients receiving 
apremilast 30 mg twice daily, and 61.5% (EAIR/100 patient-
years, 258.8) receiving apremilast 20 mg twice daily reported an 
AE. Across all exposure periods examined, most AEs were mild 
to moderate in severity. During the placebo-controlled period, 
similar rates of serious AEs (SAEs) were observed among patients 
receiving either dose of apremilast compared with placebo. Dur-
ing weeks 0 to ≤52, 6.5% (EAIR/100 patient-years, 7.9) of patients 
receiving apremilast 30 mg twice daily and 5.6% (EAIR/100 
patient-years, 6.8) receiving 20 mg twice daily reported an SAE; 
the incidence of SAEs during the longer-term apremilast-exposure 
periods was generally similar (Table 2).
The most common AEs occurring in 5% or more of patients 
in any treatment group during the placebo-controlled period 
were diarrhea (placebo, 2.8%; apremilast 30 mg, 16.5%; apremi-
last 20 mg, 12.6%), nausea (placebo, 4.6%; apremilast 30 mg, 
16.1%; apremilast 20 mg, 10.0%), upper respiratory tract infec-
tion (placebo, 3.0%; apremilast 30 mg, 6.0%; apremilast 20 mg, 
7.0%), and headache (placebo, 4.6%; apremilast 30 mg, 11.5%; 
apremilast 20 mg, 8.4%), with greater AE rates reported with 
apremilast treatment compared with placebo (Table 2). During 
weeks 0 to ≤52, AEs occurring in 5% or more of apremilast-ex-
posed patients were diarrhea (13.9%; EAIR/100 patient-years, 
18.6), nausea (12.3%; EAIR/100 patient-years, 16.0), headache 
(9.4%; EAIR/100 patient-years, 12.1), upper respiratory tract 
infection (9.1%; EAIR/100 patient-years, 11.5), and nasophar-
yngitis (6.2%; EAIR/100 patient-years, 7.7). Lower rates of diar-
rhea, nausea, and headache were observed during weeks >52 
to ≤104 and >104 to ≤156 than was observed during weeks 0 
to ≤52.
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Discontinuations due to AEs during the placebo-controlled 
phase occurred in 4.2% of patients receiving placebo, 7.2% 
receiving apremilast 30 mg twice daily, and 5.6% receiving 20 mg 
twice daily; during weeks 0 to ≤52, 7.8% receiving apremilast 
30 mg twice daily and 7.2% receiving apremilast 20 mg twice 
daily discontinued use because of AEs. During weeks >52 to 
≤104 and >104 to ≤156, fewer patients discontinued because 
of AEs (Table 2).
The majority of diarrhea and nausea events occurred during 
the first 2 weeks of apremilast treatment (Figure 3) and resolved 
within 30 days. Diarrhea and nausea events were predomi-
nantly mild or moderate in severity across all apremilast-exposure 
periods examined. The incidence of these GI AEs was low with 
longer-term apremilast exposure (Table 2).
Likewise, GI AEs leading to discontinuation in more than 
two patients in any treatment group were infrequent with longer-
term apremilast exposure (Table 3). Discontinuations due to 
diarrhea and nausea were low and most occurred among apremi-
last-treated patients during the placebo-controlled period. Among 
patients receiving apremilast 30 mg twice daily, one patient dis-
continued use because of diarrhea during weeks >52 to ≤104, 
and none discontinued due to diarrhea or nausea during weeks 
Figure 1. Patient disposition through week 156 in apremilast patients, as treated. All patients exposed to apremilast are included, regardless 
of when the apremilast exposure started. For follow-up, 0 to 52 weeks or less is defined as 364 days or less, more than 52 to 104 weeks or 
less is defined as 365 to 728 days, and more than 104 to 156 weeks or less is defined as 729 to 1092 days. Abbreviation: BID, twice daily.
Figure 2. Withdrawal due to any reason from start of apremilast 30 mg twice daily (A) and apremilast 20 mg twice daily (B). Patients’ day of 
withdrawal is defined as the day after their last day on apremilast. Patients who took at least one dose of apremilast and did not discontinue by 
week 156 are censored. The n values represent the number of patients available at the time point. Abbreviation: BID, twice daily.
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>104 to ≤156. Among patients receiving apremilast 20 mg twice 
daily, none discontinued because of diarrhea or nausea during 
weeks >52 to ≤104, and one discontinued due to diarrhea during 
weeks >104 to ≤156.
Fewer than 2% of patients experienced an AE of weight 
decrease during the apremilast-exposure periods (apremilast 
30 mg: weeks 0 to ≤52, 13/721 [1.8%], weeks >52 to ≤104, 
1/520 [0.2%], weeks >104 to ≤156, 1/443 [0.2%]; apremilast 
20 mg: weeks 0 to ≤52, 9/720 [1.3%], weeks >52 to ≤104, 2/508 
[0.4%], weeks >104 to ≤156, 0/422 [0.0%]). During the place-
bo-controlled period, 22.1% of patients treated with apremilast 
with weight loss greater than 5% experienced AEs of diarrhea, 
14.5% experienced nausea, and 2.3% experienced vomiting.
During weeks 0 to ≤52, the mean percent change from 
baseline weight (kg) was −1.03% in patients receiving apremi-
last 30 mg twice daily, with similar weight change observed with 
apremilast 20 mg twice daily; weight change was generally simi-
lar for the apremilast-exposure periods (weeks >52 to ≤104 and 
weeks >104 to ≤156) (Table 4). Most patients maintained their 
weight within 5% of baseline during each of the three long-term 
apremilast-exposure periods. Results with apremilast 20 mg twice 
daily were similar (Table 4).




30 mg BID 
n = 497
20 mg BID 
n = 501
Age, mean (SD), y 50.5 (11.6) 50.6 (11.4) 49.8 (11.7)
Female, n (%) 255 (51.5) 275 (55.3) 269 (53.7)
Race, n (%)
White 462 (93.3) 472 (95.0) 463 (92.4)
Black 4 (0.8) 1 (0.2) 3 (0.6)
Asian 18 (3.6) 11 (2.2) 23 (4.6)
Native American, Alaskan, Hawaiian, Pacific Islander 3 (0.6) 1 (0.2) 3 (0.6)
Other 7 (1.4) 12 (2.4) 9 (1.8)
Region, n (%)
North America 164 (33.1) 170 (34.2) 169 (33.7)
Europe 220 (44.4) 221 (44.5) 223 (44.5)
Rest of world 111 (22.4) 106 (21.3) 109 (21.8)
Weight, mean (SD), kg 86.4 (21.1) 84.5 (19.6) 86.1 (21.2)
Body mass index, mean (SD), kg/m2 30.0 (6.5) 29.7 (6.2) 30.1 (6.8)
PsA clinical features, mean (SD)
PsA duration, years 7.3 (7.3) 7.5 (7.8) 7.6 (7.7)
SJC (0-76) 11.0 (8.0) 11.6 (8.2) 11.4 (8.9)
TJC (0-78) 19.9 (14.8) 21.9 (15.2) 21.1 (16.4)
MASES (0-13) 3.1 (3.5) 3.0 (3.4) 2.9 (3.4)
Dactylitis severity score (0-20) 1.4 (2.7) 1.5 (2.7) 1.4 (2.8)
CDAI score (0-76) 26.6 (11.8) 27.6 (11.5) 26.7 (12.0)
DAS-28 (CRP) 4.7 (1.1) 4.7 (1.0) 4.6 (1.1)
CRP, mg/dl 1.03 (1.43) 0.96 (1.40) 0.98 (1.73)
Psoriasis duration, years 17.1 (13.4) 17.4 (13.0) 17.2 (13.5)
PASI score (0-72)b 8.4 (8.8) 8.3 (7.9) 7.5 (6.9)
Psoriasis-involved BSA, % 7.8 (15.5) 7.3 (13.3) 6.8 (11.9)
PsA treatment patterns, n (%)
Prior use of conventional DMARDs only 375 (75.8) 382 (76.9) 383 (76.4)
Prior use of biologics 112 (22.6) 107 (21.5) 115 (23.0)
TNF inhibitor 104 (21.0) 98 (19.7) 108 (21.6)
Prior biologic therapeutic failures 39 (7.9) 35 (7.0) 42 (8.4)
Baseline conventional DMARD use 325 (65.7) 319 (64.2) 329 (65.7)
Methotrexate (mean dose, 15.4 mg/wk) 276 (55.8) 261 (52.5) 277 (55.3)
Leflunomide (mean dose, 18.1 mg/d) 33 (6.7) 38 (7.6) 39 (7.8)
Sulfasalazine (mean dose, 1.96 g/d) 45 (9.1) 46 (9.3) 44 (8.8)
Baseline corticosteroid use 48 (9.7) 64 (12.9) 95 (19.0)
Baseline NSAID use 340 (68.7) 355 (71.4) 360 (71.9)
Abbreviations: BID, twice daily; BSA, psoriasis-involved body surface area; CDAI, Clinical Disease Activity 
Index; CRP, C-reactive protein; DAS-28, 28-item Disease Activity Score; DMARD, disease-modifying 
antirheumatic drug; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; NSAID, nonsteroidal 
anti-inflammatory drug; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SD, standard 
deviation; SJC, swollen joint count; TJC, tender joint count; TNF, tumor necrosis factor.
a The n reflects the number of patients who received at least one dose of the study medication; actual 
number of patients with data available for each parameter may vary. 
b Examined among patients with psoriasis involvement of the BSA of at least 3% at baseline who had 
data at baseline. 
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Other AEs of interest. Overall, serious infection rates dur-
ing the placebo-controlled phase were low among patients receiv-
ing apremilast 30 mg twice daily (0.6%) and placebo (0.4%). No 
patients receiving apremilast 20 mg twice daily reported a serious 
infection during the placebo-controlled period. During each of 
the three apremilast-exposure periods, rates of serious infections 
remained low (≤1.6%) in patients receiving either dose of apremilast.
A serious opportunistic infection (cause unknown) occurred 
in one patient receiving placebo (ie, suppurative tenosynovitis) 
during weeks 0 to 24. No serious opportunistic infections were 
experienced with apremilast 30 mg twice daily up to 156 weeks. 
One (0.2%) patient, a 60-year-old female who received 20 mg of 
apremilast twice daily, experienced a serious opportunistic infec-
tion (Herpes zoster limited to one dermatome) during weeks >104 
to ≤156. The event was rated as mild in severity.
No cases of tuberculosis (new or reactivation) were reported 
with either apremilast dose, despite study sites in areas with 
endemic tuberculosis, such as South Korea, South Africa, and the 
Russian Federation (21), and also despite enrollment of patients 
with a tuberculosis-related medical history (terms reported: latent 
tuberculosis, n = 12; pulmonary tuberculosis, n = 5; and other 
tuberculosis, n = 6).
AEs of depressed mood and depression during the place-
bo-controlled period were reported in zero (0.0%) and four (0.8%) 
patients receiving placebo, one (0.2%) and four (0.8%) receiving 
apremilast 30 mg twice daily, and one (0.2%) and eight (1.6%) 
receiving apremilast 20 mg twice daily, respectively.
During weeks 0 to ≤52, AEs of depressed mood and depres-
sion were reported in 4 (0.6%) and 7 (1.0%) patients receiving 
apremilast 30 mg twice daily, and 2 (0.3%) and 17 (2.4%) patients 
receiving apremilast 20 mg twice daily, respectively. A history of 
depression and/or bipolar disorder was present among patients 
receiving apremilast 30 mg twice daily (n = 73 [14.7%]) and 20 mg 
twice daily (n = 84 [16.8%]). No increase in the rates of depression 
or depressed mood was observed with longer-term apremilast 
exposure.
Figure 3. Time to onset of diarrhea with apremilast 30 mg twice daily (versus placebo). Percentages in each category of onset are based on 
the total number of events in each treatment group. Patients who received placebo and then switched to apremilast could contribute events to 
both treatment groups. Data after day 30 are not displayed. Abbreviations: AE, adverse event; BID, twice daily.
Table 3. GI AEs leading to discontinuation in more than two patients
Patientsc, 
n (%)
Placebo-Controlled Perioda Apremilast-Exposure Periodb
Weeks 0 to 24 Weeks 0 to ≤52 Weeks >52 to ≤104 Weeks >104 to ≤156
Placebo 
n = 495
Apremilast Apremilast Apremilast Apremilast
30 mg BID 
n = 497
20 mg BID 
n = 501
30 mg BID 
n = 721
20 mg BID 
n = 720
30 mg BID 
n = 520
20 mg BID 
n = 508
30 mg BID 
n = 443
20 mg BID 
n = 422
Any GI AE 6 (1.2) 25 (5.0) 13 (2.6) 35 (4.9) 19 (2.6) 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.2)
Diarrhea 3 (0.6) 11 (2.2) 5 (1.0) 14 (1.9) 6 (0.8) 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.2)
Nausea 3 (0.6) 13 (2.6) 7 (1.4) 16 (2.2) 8 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Vomiting 0 (0.0) 3 (0.6) 1 (0.2) 6 (0.8) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Upperabdominal 
pain
0 (0.0) 2 (0.4) 1 (0.2) 3 (0.4) 4 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Abbreviations: AE, adverse event; BID, twice daily; GI, gastrointestinal.
a Includes data up to week 16 for early escaped placebo patients and up to week 24 for all other patients. 
b Includes all patients who received apremilast during the exposure interval, relative to the start of apremilast administration. 
c Patients are counted under each AE that led to apremilast discontinuation. 
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No patients receiving placebo (0/495) or apremilast 30 mg 
twice daily (0/497) experienced suicidal ideation or suicide attempt 
during the placebo-controlled period; instances of suicidal ideation 
(n = 1) and suicide attempt (n = 1) were observed in 0.4% (2/501) of 
patients receiving apremilast 20 mg twice daily. No additional AEs 
of suicidal ideation or suicide attempt occurred in patients receiv-
ing apremilast 20 mg twice weekly during weeks 0 to ≤52, and nei-
ther of these AEs was reported in any patient receiving apremilast 
30 mg twice daily during this apremilast treatment period.
During weeks >52 to ≤104, a patient receiving apremilast 
30 mg twice daily with a history of depression, bipolar affective 
disorder, and physical/emotional abuse attempted suicide (1/520 
[0.2%]), and a patient receiving apremilast 20 mg twice daily expe-
rienced suicidal ideation (1/508 [0.2%]). Neither of these AEs was 
observed in any patient during weeks >104 to ≤156.
Rates (EAIRs/100 patient-years of apremilast exposure) 
of malignancies were low across the apremilast dose groups 
throughout the 156-week exposure period (weeks 0 to ≤52: 0.6; 
weeks 0 to ≤104: 0.7; weeks 0 to ≤156: 0.9) (Supplementary 
Table 1).
MACEs were defined to include sudden unwitnessed death, 
cardiovascular death (ie, sudden cardiac death, death due to 
MI, heart failure, stroke, or other cardiovascular death), MI, and 
stroke. Overall, across both apremilast dose groups, EAIRs per 
100 patient-years of apremilast exposure for adjudicated MACEs 
were low and remained consistent through weeks 0 to ≤52 (0.2), 
weeks 0 to ≤104 (0.4), and weeks 0 to ≤156 (0.5). MI and acute 
MI were the most frequently reported events over 156 weeks 
(n = 9), with five occurring in patients 65 years of age and older; 
relevant medical history for cardiac disorders included coronary 
artery disease. Other MACEs that occurred during the 156 weeks 
of apremilast exposure were ischemic stroke (n = 2; 0.1 EAIR/100 
patient-years), cerebrovascular accident (n = 1; 0.0 EAIR/100 
patient-years), cerebral infarction (n = 1; 0.0 EAIR/100 patient-
years), and brain stem stroke (n = 1; 0.0 EAIR/100 patient-years) 
(Supplementary Table 1).
Table 4. Weight change from baseline in the apremilast-exposure perioda
Apremilast
Weeks 0 to ≤52 Weeks >52 to ≤104 Weeks >104 to ≤156
30 mg BID 
n = 721
20 mg BID 
n = 720
30 mg BID 
n = 520
20 mg BID 
n = 508
30 mg BID 
n = 443
20 mg BID 
n = 422
Weight change from baseline,  
 mean, kgb
−0.92 −1.20 −1.32 −1.36 −1.31 −1.14
Percent weight change from  
 baseline, mean, kgb
−1.03 −1.26 −1.44 −1.30 −1.37 −1.09
Patients with ≥5% change in weight  
 from baseline, n/mc (%)b
>5% loss from baseline 99/711 (13.9) 103/708 (14.5) 123/517 (23.8) 117/501 (23.4) 99/441 (22.4) 100/419 (23.9)
>5% gain from baseline 36/711 (5.1) 27/708 (3.8) 44/517 (8.5) 58/501 (11.6) 46/441 (10.4) 57/419 (13.6)
Abbreviation: BID, twice daily.
a Includes all patients who received apremilast during the exposure interval, relative to the start of apremilast administration. 
b Data include the last postbaseline value during the exposure interval, including data up to 28 days after the last dose of apremilast (including 
the observational follow-up visit). 
c n/m indicates the number of patients with 5% or greater change (loss or gain) in weight from baseline/number of patients with postbaseline 
weight data available during the exposure interval, including data up to 28 days after the last dose of apremilast (including the observational 
follow-up visit). 
Table 5. Clinically meaningful abnormalities in select clinical laboratory variables in the apremilast-exposure perioda
Patients, n/mb (%)
Apremilast
Weeks 0 to ≤52 Weeks >52 to ≤104 Weeks >104 to ≤156
30 mg BID 
n = 721
20 mg BID 
n = 720
30 mg BID 
n = 520
20 mg BID 
n = 508
30 mg BID 
n = 443
20 mg BID 
n = 422
ALT >3x ULN 9/713 (1.3) 8/713 (1.1) 2/518 (0.4) 1/502 (0.2) 2/442 (0.5) 2/419 (0.5)
AST >3x ULN 4/713 (0.6) 4/713 (0.6) 1/518 (0.2) 1/502 (0.2) 3/442 (0.7) 3/419 (0.7)
Creatinine >1.7x ULN 1/713 (0.1) 1/713 (0.1) 0/518 (0.0) 0/502 (0.0) 0/442 (0.0) 1/419 (0.2)
Leukocytes <1.5, 109/l 0/713 (0.0) 0/712 (0.0) 0/517 (0.0) 0/503 (0.0) 0/442 (0.0) 0/419 (0.0)
Neutrophils <1, 109/l 2/713 (0.3) 4/712 (0.6) 3/517 (0.6) 2/502 (0.4) 2/442 (0.5) 1/419 (0.2)
Platelets <75, 109/l 0/713 (0.0) 0/712 (0.0) 0/517 (0.0) 1/503 (0.2) 1/441 (0.2) 1/419 (0.2)
Hemoglobin <10.5 g/dl male, 
<8.5 g/d female
5/713 (0.7) 5/712 (0.7) 4/517 (0.8) 0/503 (0.0) 5/442 (1.1) 2/419 (0.5)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily.
a Represents all patients who received apremilast during the exposure interval, relative to the start of apremilast administration. 
b Represents the number of patients with one or more occurrences of the abnormality at any time point/number of patients with one or more 
postbaseline values. 
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During all three apremilast-exposure periods, few patients 
experienced clinically meaningful abnormalities in hematology and 
clinical chemistry postbaseline laboratory values, and most val-
ues returned to baseline with continued treatment. Additionally, 
observed clinically meaningful abnormalities in laboratory values 
had no meaningful treatment or dose effect (Table 5). Most patients 
exhibited values within the normal range at baseline for all labora-
tory parameters evaluated, including neutrophils, leukocytes, and 
platelets, and the majority of patients continued to maintain values 
within the normal range for all parameters throughout longer-term 
apremilast exposure to 156 weeks or fewer. Clinically important 
shifts in patients with normal baseline laboratory values were infre-
quent (Supplementary Table 2). Longer-term apremilast exposure 
lacked new safety signals and was consistent with previously 
reported safety results up to week 52 (17–19).
DISCUSSION
Based on the analysis of clinical trial cohorts of patients with 
active PsA (N = 1493), apremilast demonstrated an acceptable 
safety profile and was generally well tolerated for up to 156 weeks 
in the PALACE 1, 2, and 3 studies.
As with other PDE4 inhibitors, apremilast was associated 
with GI AEs of predominantly mild or moderate diarrhea and 
nausea among patients in the PALACE safety population. The 
events tended to occur within the first 2 weeks of treatment and, 
with continued treatment, resolved within 30 days. The mecha-
nism of diarrhea is thought to be related to PDE4 inhibition and 
increased cyclic adenosine monophosphate levels, which lead 
to the activation of membrane chloride channels (22) and sub-
sequent fluid secretion in the gut, resulting in diluted digested 
products and watery diarrhea (23). Similarly, increases in cyclic 
adenosine monophosphate occurring centrally in neurons of the 
area postrema within the central nervous system, which controls 
emesis (24), and peripherally in gastric mucosal parietal cells, 
which subsequently increase gastric acid secretion, are thought 
to contribute to the mechanism of nausea related to PDE4 inhibi-
tion (25). If patients develop severe diarrhea, nausea, or vomiting 
with apremilast use, a dose reduction or suspension of apremilast 
should be considered, as noted in package labeling.
During the placebo-controlled period, 4.6% of patients 
receiving placebo, 12.3% receiving apremilast 30 mg twice daily, 
and 14.0% receiving apremilast 20 mg twice daily experienced 
weight loss greater than 5%. Of these patients, 4.3%, 24.6%, 
and 20.0% experienced diarrhea, 4.3%, 9.8%, and 18.6% expe-
rienced nausea, and 0.0%, 3.3%, and 1.4% experienced vom-
iting, respectively. During the long-term apremilast-exposure 
period, approximately 20% of patients experienced weight loss 
greater than 5%. Weight loss was not associated with GI AEs of 
diarrhea or nausea and was not linked to major consequences 
typically associated with abnormal or severe weight loss. Weight 
loss observed with apremilast in the current analyses was con-
sistent with that observed in the ESTEEM phase III studies in 
patients with moderate to severe plaque psoriasis. Inhibition of 
PDE4 increases plasma levels of glucagon-like peptide-1 (GLP-1) 
(26), which stimulates insulin secretion and inhibits glucagon 
secretion (27). GLP-1 mimetics are used in the treatment of type 2 
diabetes and are associated with weight loss (28), and a GLP-1‒
related mechanism may account for the weight loss documented 
with PDE4 inhibitors, including apremilast. As per guidance in 
apremilast package labeling, if unexplained or clinically significant 
weight loss occurs, weight loss should be evaluated and discon-
tinuation of apremilast should be considered.
Although depression has been reported as an AE with PDE4 
inhibitors (29), rates of depression in this analysis were not ele-
vated when compared with rates seen in patients with PsA (13). 
Attempted suicide and suicidal ideation during the long-term 
exposure period were rare. According to data from the 2008 
National Survey on Drug Use and Health, 3.7% of individuals 18 
years of age or older in the United States had thoughts of sui-
cide, 1.0% had made plans to commit suicide, and 0.5% had 
attempted suicide (30).
Concerns with long-term treatment options for PsA include 
serious opportunistic infections, MACEs, and malignancies. In this 
analysis, rates for these events were low, with no increase over 
long-term exposure. MACEs and malignancy rates were aligned 
with those in the general PsA population (31). Background inci-
dence rates per 100 patient-years of 0.39 for acute MI and 0.32 
for stroke have been reported in a cohort of PsA patients in a large 
US claims database analysis (31).
Rates of overall malignancy reported in the literature vary 
depending on the approach used in capturing and verifying such 
events. An incidence of 0.56 per 100 patient-years in PsA patients 
was reported in an analysis of the CORRONA database (32), and 
a 0.98 standardized incidence rate was reported in a cohort from 
the University of Toronto Psoriatic Arthritis Clinic (14).
Breast cancer and nonmelanoma skin cancer were reported 
in 3 and 11 patients, respectively, with EAIRs in the expected range; 
background incidence rates per 100 patient-years of 0.20 for 
breast cancer and 0.21 for nonmelanoma skin cancer have been 
reported in the CORRONA analysis (32). Most other cancer types 
were reported in one patient each in the current analysis. Also con-
sistent with the CORRONA analysis (32), patients 65 years of age 
or older in the current analysis had slightly higher rates of malig-
nancy overall, but there were a limited number of events (n = 5) and 
only one case for each of the cancer types encountered.
Despite the availability of DMARD and biologic treatments for 
patients with active PsA, a desire still exists for long-term therapy 
that does not require routine laboratory monitoring or temporary 
or permanent discontinuation due to laboratory abnormalities or 
tolerability issues. The current analysis further demonstrates that 
discontinuations of apremilast treatment due to AEs remains low 
over time and routine laboratory monitoring may not be required; 
clinically meaningful abnormalities were infrequent and transient, 
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and most patients maintained laboratory parameters within the 
normal range across all three apremilast-exposure periods.
The studies discussed in the current analysis did not include 
a long-term placebo-controlled arm; therefore, it is not possible 
to assess the long-term rates of AEs within this study for patients 
not on apremilast. Because of the controlled setting associated 
with clinical trials, and the limited comorbidities and biologic fail-
ures in the PALACE population, results from our analyses may 
not be easily interpreted to PsA patients in the general commu-
nity. Data on the efficacy and safety of apremilast in the real-
world setting are providing insight into the use of apremilast in 
the general population (33,34).
In conclusion, this pooled safety analysis of patients with 
active PsA demonstrates that long-term treatment with apremilast 
is generally safe and well tolerated, with no need for routine lab-
oratory monitoring; no new safety concerns were identified with 
long-term treatment.
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